For immediate release |
21 March 2022 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Statement regarding potential acquisition
Alliance Pharma plc (AIM: APH), the international healthcare group, confirms that it is currently in discussions with a third party regarding a potential acquisition of two products in the US. If any acquisition did occur the total consideration for both products in aggregate would be no more than $20m.
There can be no certainty that these discussions will result in a transaction and a further announcement by the Company will be made as and when appropriate.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (withdrawal) act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under article 17 of MAR.
For further information:
|
Alliance Pharma plc Head of Investor Relations: Cora McCallum |
+44 (0)1249 466 966 |
|
Buchanan Mark Court / Sophie Wills / Hannah Ratcliff |
+ 44 (0)20 7466 5000 |
|
Numis Securities Limited Nominated Advisor: Freddie Barnfield / Duncan Monteith Corporate Broking: James Black |
+ 44 (0)20 7260 1000 |
|
Investec Bank plc Corporate Finance: Daniel Adams Corporate Broking: Patrick Robb |
+44 (0)20 7597 5970 |
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDSTRUAUORUBUOUAR
The service was requested through Alliance Pharma PLC. To modify your subscription, please subscribe again. If you no longer wish to receive these emails, you may unsubscribe at any time.
Supplied